SEC Form 4 · accession 0001104659-17-041906
Nabriva Therapeutics Legacy plc · NBRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles A Rowland Jr.
Director
Period of report
Jun 23, 2017
Accepted (ET)
Jun 27, 2017 · 9:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001703287
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1,F3 | — | Jun 23, 2017 | J | 16,000 | A | — | Jul 5, 2025 | Ordinary Shares | 16,000 | 16,000 | D |
| Stock OptionF4,F5 | — | Jun 23, 2017 | J | 10,100 | A | — | Aug 25, 2026 | Ordinary Shares | 10,100 | 10,100 | D |
Explanation of responses
- F1The exercise price is 6.618 Euro.
- F2Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc.
- F3This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2019. This option vests on a monthly pro-rata basis at the end of each successive month following August 31, 2016.
- F4The exercise price is 6.634 Euro.
- F5This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2017. One hundred percent (100%) of the option will vest on August 31, 2017.